EMA Panel Backs Pretomanid for Drug-Resistant TB EMA Panel Backs Pretomanid for Drug-Resistant TB
Pretomanid FGK, in combination with bedaquiline and linezolid, is for adults with extensively drug-resistant, treatment-intolerant, or nonresponsive multidrug-resistant tuberculosis.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 31, 2020 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news
Fostemsavir Active in Multidrug-Resistant HIV-1 Infection
THURSDAY, March 26, 2020 -- Amongpatients with multidrug-resistant HIV-1 infection who have limited therapy options, reductions in HIV-1 RNA level were significantly greater in those who received fostemsavir compared with placebo during the first... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 26, 2020 Category: Pharmaceuticals Source Type: news
Treatment of Multidrug-Resistant Gram-Negative SSIs Treatment of Multidrug-Resistant Gram-Negative SSIs
SSIs caused by multidrug-resistant gram-negative bacteria can pose treatment challenges. Learn about the currently available therapeutic options as well as those under development.Current Opinion in Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2020 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news
Developing a novel oral antibiotic to treat multidrug-resistant gonorrhea
(Penn State) Up to $2.86M has been awarded to a research team including Penn State scientists and the biopharmaceutical company Microbiotix to develop a new oral antibiotic to treat multidrug-resistant gonorrhea. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 19, 2020 Category: International Medicine & Public Health Source Type: news
New Weapon in Fight Against Multidrug-Resistant TB
Title: New Weapon in Fight Against Multidrug-Resistant TBCategory: Health NewsCreated: 3/4/2020 12:00:00 AMLast Editorial Review: 3/5/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - March 5, 2020 Category: Respiratory Medicine Source Type: news
New Weapon in Fight Against Multidrug-Resistant TB
WEDNESDAY, March 4, 2020 -- While the world ' s focus is trained on the new coronavirus, a groundbreaking clinical trial finds researchers battling a tough-to-treat form of an " old " infectious disease, tuberculosis.
TB is a bacterial infection that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 4, 2020 Category: General Medicine Source Type: news
ACTG to present new HIV and TB research at CROI 2020
(University of California - Los Angeles Health Sciences) ACTG investigators will present data in oral presentations and themed discussions on the impact of chronic antiretroviral therapy (ART) on a novel metric of the HIV reservoir, predictors of multidrug resistant tuberculosis (MDR-TB) in resource-limited settings, findings from the first HIV cure trial that exclusively enrolled women, and interactions between contraceptives and TB drugs and the vaginal microbiome. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 3, 2020 Category: Infectious Diseases Source Type: news
Notes from the Field: Carbapenem-resistant Klebsiella pneumoniae with mcr-1 Gene Identified in a Hospitalized Patient - Wyoming, January 2019
In December of 2018, Wyoming identified the state ' s first case of carbapenem-resistant Enterobacteriaceae (CRE) containing mcr-1, which is a gene that can make bacteria resistant to colistin, a drug that can be the last resort for some multidrug-resistant infections like CRE. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - February 13, 2020 Category: American Health Tags: Antibiotic and Antimicrobial Resistance Carbapenem Resistant Enterobacteriaceae (CRE) MMWR Morbidity & Mortality Weekly Report Carbapenem Resistant Enterobacteriaceae CRE Source Type: news
Impact of Ibalizumab for People With Multidrug-Resistant HIV Impact of Ibalizumab for People With Multidrug-Resistant HIV
Is ibalizumab an effective and financially feasible therapeutic option for those with multidrug-resistant HIV?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 30, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
Candida auris outbreak: Mortality, interventions and cost of sustaining control
Candida auris has recently emerged as a global cause of multidrug resistant fungal outbreaks. An outbreak occurred at a tertiary care center in London in 2016. Transmission characteristics, interventions, patient outcomes and cost of resources are described. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 16, 2020 Category: Consumer Health News Source Type: news
Taking one for the team: How bacteria self-destruct to fight viral infections
(University of California - San Diego) UC San Diego School of Medicine researchers have discovered how a new immune system works to protect bacteria from phages, viruses that infect bacteria -- new information that could be leveraged to improve treatment of multidrug-resistant bacterial infections by refining phage therapy. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 10, 2020 Category: Infectious Diseases Source Type: news
RCPCH demands urgent action on air quality
Air pollution single greatest environmental threat to public health in the UK, especially for children and deprived communities Related items fromOnMedica Pollution kills 1.7 million children, says WHO Should we have compulsory measles vaccination at school entry? Multidrug-resistant TB spreads less easily than ‘normal’ TB Fewer lung symptoms in children as air pollution levels drop Texting can improve flu jab uptake (Source: OnMedica Latest News)
Source: OnMedica Latest News - January 9, 2020 Category: UK Health Source Type: news
Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia
The manufacturer of ceftolozane with tazobactam anticipates that it will be used in line with good antimicrobial stewardship, on the advice of a microbiologist, to treat critically ill ventilated adults with HAP and VAP, who are deteriorating or not responding to initial antibiotic therapy, and who have confirmed or highly suspected Pseudomonas aeruginosa. Specialists involved in producing this evidence summary consider that ceftolozane with tazobactam provides a potentially useful alternative for treating some adults with HAP and VAP who have limited treatment options because they have infections suspected or proven to be...
Source: Current Awareness Service for Health (CASH) - December 19, 2019 Category: Consumer Health News Source Type: news
Drug-Susceptible and Multidrug-Resistant M. tuberculosis Drug-Susceptible and Multidrug-Resistant M. tuberculosis
This report describes an uncommon case of drug-susceptible and multidrug-resistant tuberculosis due to a mixed-strain infection.Emerging Infectious Diseases (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 16, 2019 Category: Infectious Diseases Tags: Infectious Diseases Journal Article Source Type: news
From cancer medication to antibiotic
(Technical University of Munich (TUM)) Antibiotic-resistant bacteria are increasingly the source of deadly infections. A team of scientists from the Technical University of Munich (TUM) and the Helmholtz Center for Infection Research (HZI) in Braunschweig have now modified an approved cancer drug to develop an active agent against multidrug-resistant pathogens. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 16, 2019 Category: Infectious Diseases Source Type: news
